• Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs
• Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications
• The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021
• Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product
• The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development

Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is working to develop novel solutions for diseases that otherwise have unmet medical needs, focusing its flagship initiative on fibromyalgia and binge eating conditions with a team of experienced professionals and skilled partners set to accelerate the development of its products. Tryp’s TRP-8802 synthetic psilocybin Active Pharmaceutical Ingredient (“API”) will soon be used to initiate Phase 2a clinical trials at the University of Florida for efficacy in treating specific neurologic causes of eating disorders — primarily hyperphagia, which is a condition in which the patients never feel full, so they are continually wanting to eat. Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (“PFN”)(TM) program is also focused on the chronic pain associated with fibromyalgia. The novelty of developing psychedelic substances for medicinal purposes requires that the program be led by individuals with significant drug development experience. Tryp’s team of executives and advisors made up of deep understanding gained through their work in large pharma, emerging pharma, drug approvals, psychedelics and capital markets, as noted in a recent NetworkNewsAudio broadcast (https://ibn.fm/P2SXq). The company’s executive team boasts decades working in leadership positions with Genzyme, Unigene Laboratories, Syntex, Nventa Biopharmaceuticals, Dow Chemical, ImmunoPrecise, Jubilant, and other organizations. Tryp’s COO, Tom D’Orazio, has helped shepherd two cancer drugs through the approval process with Health Canada, and the company’s Vice President, Manufacturing, Larry Norder, worked with early-stage research, preclinical and clinical developments for the blockbuster nonsteroidal anti-inflammatory drug Naproxen, the generic name for pain-reliever Aleve. Pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida is directing the investigation of Tryp’s TRP-8802 psilocybin product. As director of University of Florida Health’s Prader-Willi Syndrome (“PWS”) Program and professor in the Division of Pediatric Endocrinology at the University of Florida Department of Pediatrics, she follows one of the largest cohorts of PWS patients in the world. PWS is a genetic disorder involving chromosomal loss or alteration whose patients experience difficulties adapting to changes, uncontrolled mood, insatiable hunger — known clinically as hyperphagia — and food impulsivity. This frequently leads to the negative health effects associated with obesity, although researchers have noted that the lockdowns resulting from the COVID pandemic have led to significant weight loss in a large percentage of patients (https://ibn.fm/F3R2x). Pharmaceutical research companies are partnering with Tryp to provide support services for the development of its synthetic psilocybin product. Psychedelic therapy educational platform Fluence will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials (https://ibn.fm/qxc92). Global novel pharmaceutical product contract research organization (“CRO”) Clinlogix will provide its support services for clinical trials (https://ibn.fm/8b5kY), and Tryp announced on May 25 that global pharmaceutical contract development and manufacturing organization Alcami Corporation will support development of proprietary oral formulations for TRP-8802, which is manufactured by Albany Molecular Research, Inc. (“AMRI”) (https://ibn.fm/TlTXi). Tryp expects to manufacture its initial batch of cGMP psilocybin API in September 2021, according to the company’s latest news release. Alcami and Tryp will then work together to develop the analytical methods and the final formulation for the oral psilocybin product. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million
• Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises
• Company subsidiaries reached several milestone achievements throughout the quarter.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, reported its financial results for first quarter 2021, the period ending March 31, 2021 (https://ibn.fm/kUVwH). The company also released key business updates along with its financial numbers. “The combination of equity transactions and retirement of our outstanding debt has brought significant value to our shareholders this quarter, as total stockholders’ equity increased by nearly $33 million,” said POAI Chief Executive Officer J. Melville Engle. “The Company’s subsidiaries continue to create value for our growing customer base as well.” POAI’s $35.5 million stockholders’ equity figure increased from the $2.6 million the company reported on Dec. 31, 2020. This included net proceeds of $35.6 million from a recent private placement, a registered direct offering and warrant exercises, as well as a balance of $27.3 million cash and cash equivalents. POAI’s balance sheet strengthened through the quarter as the company fully repaid outstanding debt incurred from 2018 to 2020. The company noted that its subsidiary Soluble Biotech had signed a contract with a pharmaceutical company to use Soluble Biotech’s proprietary protein formulation technology. Researchers from Helomics, another POAI subsidiary, also completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease, the report noted. “Soluble Biotech’s contract with this pharmaceutical company will allow the use of Soluble Biotech’s proprietary protein formulation technology in the improvement of the solubility and stability of a protein therapeutic destined for future clinical use. This may also lead to a strategic partnership for other therapeutics currently being developed by this pharma company,” reported Engle, who went on to note key highlights for the company’s other subsidiaries. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021. PeDAL brings together the key Helomics assets of real-world longitudinal data on 150,000 tumor drug response profiles and our clinically validated tumor assay with Quantitative Medicine’s active machine learning (‘AI’) technology. We believe the PeDAL platform will revolutionize early discovery and allow our pharma partners to significantly improve the chances that new drugs will translate into the clinic, saving costs and time,” said Engle, who also added that Helomics has initiated an internal drug repositioning project in ovarian cancer that the company believes will provide validation data to drive its commercial discussions and as potentially valuable intellectual property for licensing. Finally, TumorGenesis, another POAI subsidiary, is providing products that aid researchers at a top-tier laboratory to capture, culture and identify how ovarian cancer cells “break through” the protective lining in the abdomen—a valuable contribution in the understanding of how these cells migrate outside the abdominal cavity. “The results of this research could represent several billion dollars in future revenue for biotech and pharma companies, underscoring the value of TumorGenesis’s services and product lines to our customers,” Engle said. “We are pleased with the direction of the Company and how its subsidiaries are moving.  We are working towards leveraging our databases and intellectual property to fill the unmet market needs of pharmaceutical companies so they may deliver more targeted approaches to therapy, increasing our value to them while we all work together to improve patient outcomes,” he concluded. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Company is the first music industry disruptor to leverage non-fungible tokens that allow music fans to share in 50% of the income brought in by various music royalties
• NFT Series 1 pre-sale exceeded $1 million, with three NFTs selling for $200,000; to be followed by three other NFT series in the future
• BAND Royalty launches first ever Music-Only NFT Marketplace on its own website
• Plans in motion to expand music performance royalty catalogue with other top-tier artists and tracks, resulting in larger income streams

Entertainment tech company BAND Royalty is leveraging the unprecedented growth and popularity of non-fungible tokens to revolutionize the music industry and how fans interact with their favorite artists and music. The company set out to create a unique NFT music ecosystem that allows music lovers take their enjoyment to the next level by sharing in the royalties of their favorite songs each time they are performed. To this end, BAND Royalty has already taken the first steps by rolling out a series of 3,000 music art NFTs and launching a beta version of its own NFT marketplace – the first ever Music-Only NFT Marketplace – on its website, www.BandRoyalty.com. The company’s NFT Series 1 had a successful pre-sale of more than $1 million, with just three NFTs selling for $200,000. Featuring a limited collection of unique art that celebrates the music industry and its diversity, the BAND NFTs available in Series 1 have a starting price of 1 ETH (approximately $2,900 as of May 20, 2021). The company plans to issue three more NFT series (https://ibn.fm/QmGxj). After purchase, the NFTs can be staked in any of the three BAND Royalty Music Pools: publishing, mechanical or public performance and synchronization, allowing holders to receive a portion of royalties from each track for each royalty pool every time that track is performed by any artist. The company’s royalty pools cover an extensive catalog with tracks by some of the music industry’s most popular artists including Cher, Rihanna, Beyoncé, Jay-Z and more. Creating the first decentralized finance model based on music royalties, the company is working continuously to expand its music royalty library collection, adding more top-tier artists and tracks to its portfolio, resulting in larger income streams for NFT holders. BAND Royalty founders and blockchain experts Barnaby Andersun (BA) and Noble Drakoln (ND) discussed the company’s innovative business model and goals, as well as the rise of NFTs and future opportunities in this market during a recent appearance on The Dealmaker Show, hosted by Oren Klaff (https://ibn.fm/tdLHa). During the show, Drakoln explained that the idea behind BAND’s NFTs was to teach people exactly how musicians make money and who else is involved in the process, as well as get fans connected with artists directly. “We can get Rihanna; we can get Demi Lovato songs… Jay-Z, Beyoncé… they’re artists, but they’re not the only artists on these songs. Producers made it; writers made it. There are so many different royalty streams… we can go ahead and acquire this music for eight years, 10 years, life of rights, at any given time. That’s how BAND Royalty started,” Drakoln said. “Hopefully, we’ll change things. The goal is to really get people talking and the artists talking and changing how fans interact with their favorite artists.” As the first music industry disruptor that uses NFTs, BAND Royalty is uniquely positioned to capitalize on the NFT market’s impressive expansion. The entire cryptocurrency sector has been increasing exponentially in value and popularity, and is anticipated to reach an estimated $1.8 billion by 2027 (https://ibn.fm/hOxAD). Driven up by the explosion of NFTs and the growth of the decentralized finance market, Ether has become the second largest cryptocurrency worldwide following Bitcoin. NFT sales on the Ethereum network reached $2 billion in the first quarter of 2021, an impressive jump from the $94 million reported the previous quarter. Andersun voiced confidence that NFTs are here to stay, changing the concept of digital asset and ownership for good. “While it looks like NFTs are these hot new items that everyone wants to get because they’re sexy and cool like a fad, well guess what – TV was a fad; telephone was a fad; most of all, the internet was a fad,” Andersun said. “Then, blockchain was a fad; bitcoin was a fad. It was never going to go anywhere. Nothing was going to happen. This is how people see things.” In reality, he said, people have been looking for ways to make non-fungible, tradable digital assets since the 1980s, and NFTs are finally a reliable solution. According to Drakoln, NFT value will continue growing exponentially. “I believe, without a doubt, next year we’ll see a $100 billion year for NFTs… NFTs are very, very valuable, beyond what we’re imagining,” Drakoln said. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• Cannabis sales numbers in Michigan reaching record highs
• HENC, Blackbox strategy includes developing 120-acre Michigan farmland into cannabis cultivation

Cannabis medicinal and recreational sales numbers in Michigan are reaching record highs: year-end totals for 2020 approached $1 billion (https://ibn.fm/tCdQa), and sales in 2021 have shown even more impressive growth, with March numbers hitting a record $115.4 million (https://ibn.fm/sRj0Y) and April numbers approaching $154 million (https://ibn.fm/LOiJS). Cannabis company Hero Technologies (OTC: HENC) is paying close attention to Michigan’s performance because the company’s majority-owned subsidiary, BlackBox Systems and Technologies LLC, earlier this year signed a purchase agreement to acquire 120 acres of Michigan farmland for cannabis cultivation (https://ibn.fm/yuCi3). “Michigan generated $985 million in cannabis sales in 2020, and the program should continue to expand this year as supply becomes more available and as distribution expands,” stated a recent New Cannabis Ventures article. “So far in 2021, year-to-date combined sales are up 171% to $513.1 million.” The trend bodes well for Hero Technologies and Blackbox, whose plans for its Michigan property include building state-of-the-art sun chambers and high-tech greenhouses that produce cost-effective, high-yield cannabis year-round. In fact, the company estimates that the Michigan property supports up to 500 sun chambers, and each sun chamber can potentially generate $5 to $10 million annually in high-margin revenue. The process of obtaining a cannabis license in Michigan is a two-step process handled by Michigan’s Department of Licensing and Regulatory Affairs. The process involves meeting certain prequalification steps, which allows applicants to begin the process while seeking approved locations and facilities and also encompasses a full background investigation of all applicants and payment of a nonrefundable $6,000 fee (https://ibn.fm/5PEco). The second step is the actual license application, which identifies the specific facility license being applied for (grower, processor, provisioning center, safety compliance or secure transporter) and provides information and supporting documentation specific to the license sought. Applicants may apply for more than one facility license. “The numbers for our cannabis cultivation plan in Michigan look exceptionally strong,” said Hero Technologies CEO Gina Serkasevich. “We have thoroughly analyzed startup costs, ongoing costs and a wide range of revenue scenarios. Even our most conservative estimates, using the low end of the wholesale price range, put us over $1 billion in revenue by the end of our multiphase plan. And the upside potential is much bigger. A higher percentage of retail sales and a higher price per pound could support annual revenue from our Michigan operations in excess of $3 billion.” The company anticipates taking anywhere from five to ten years to complete its master plan for the Jackson, Michigan, property. Hero Technologies Inc. is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• CHAL finalizes acquisition of five HomeGrown retail dispensaries
• Strategic move provides exceptional geographic compatibility with Chalice
• The fact that Homegrown is profitable makes this a highly accretive acquisition for GLDFF’s earnings per share

In a state that is paving the way forward for cannabis, Chalice Brands (CSE: CHAL) (OTCQB: GLDFF), previously operating under the name Golden Leaf Holdings Ltd., is making its mark. The company recently announced a transformational acquisition that brings a chain of five Oregon-based retail dispensaries under the Chalice umbrella (https://ibn.fm/GF674). The dispensaries, previously owned by SMS Ventures LLC, known as Homegrown, are located in Portland, Salem and Albany. This transaction increases Chalice Brands’ retail store footprint from 7 to 12 locations in the state of Oregon. “We have been diligently searching for the appropriate footprint expansion for our retail business in Oregon that represented the right fit and to be in a position to fund the acquisition,” said Chalice Brands president and CEO Jeff Yapp. “Homegrown’s culture aligns perfectly within ours and provides an exceptional geographic compatibility with Chalice and offers an expansion into parts of Oregon in which Chalice does not operate currently. “We have the ability to significantly increase vertical margin revenue through the distribution of our existing edibles and extraction manufacturing as well as our own grow,” he continued. “Homegrown is a well-run retail operation with a very dedicated team at all five stores that we will continue to rely on as we go forward. The owners of Homegrown have been wonderful to work with during this process and will continue to assist us as we transition and integrate the business. Like GLH, Homegrown holds a deep commitment to prioritizing customer service with exceptional consumer transparency and building long-term relationships with people.” The first state to decriminalize small amounts of marijuana, Oregon represents the third largest cannabis market in per capita consumption in the country, reporting $275 annual cannabis spend per capita (https://ibn.fm/xcNBy). The state boasts 16.5 dispensaries per 100,000 resident, offers a stable cultivation and supply chain, and has an optimal climate for growing best-in-class cannabis. No wonder Chalice is eyeing the promising market. The acquisition announcement outlined the acquisition details: the purchase of Homegrown’s dispensaries was completed for total consideration of an estimated $9.75 million, or 0.9 times Homegrown’s first quarter 2021 annualized revenue. The fact that Homegrown is profitable makes this a highly accretive acquisition for Golden Lead Holdings’ earnings per share. It is anticipated that consumers will find Chalice Brand products on Homegrown shelves in the coming months, providing the opportunity to increase gross margins by between 5% and 10% in the newly acquired stores. “Management is excited to combine with Homegrown and fully expects to continue its migration to better valuations for shareholders as we continue to execute our acquisition strategy,” said Chalice Brands executive chair John Varghese. “As part of our West Coast-focused growth strategy, we will continue to seek acquisitions like these to demonstrate that we are good allocators of capital. We will continue to grow our business with positive cash flow from both internal organic revenue growth with stringent cost containment. On the acquisition front, we have a growing funnel of actionable and accretive targets that we are assessing and will pursue in the near term.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

While Q1 numbers are down, ISWH has net increase in total cases; the bulk of those results will appear as accounts receivable Q2 is on track for strong gains in both year-over-year and sequential terms Company’s overriding focus is on driving big results in our renewable energy cryptocurrency mining operations ISW Holdings’ (OTC: ISWH) diverse portfolio and savvy business operations has contributed to the company’s success in holding strong during a period of uncertainty. The company, which has commercial operations in both telehealth and cryptocurrency mining, recently released its financial report for first quarter 2021 (https://ibn.fm/4X42h). “Results this quarter reflect a deficit in payment collections in our telehealth and home healthcare segment, which have fallen significantly behind schedule,” said ISW Holdings president and chair Alonzo Pierce. “We have seen a net increase in total cases, but the bulk of those results will appear predominantly as accounts receivable. Q2 is on track for strong gains in both year-over-year and sequential terms. That said, our overriding focus now is on driving big results in our renewable energy cryptocurrency mining operations, which will show tangible results for the first time in our upcoming Q2 data.” While some numbers trended down, the company noted that net cash increased 2,679% on a sequential quarterly basis to $2,394,585 along with accounts receivable for the quarter increasing 73% to $67,420 and total current assets increasing 1,105% to $2,564,247. Other quarter highlights for the company included the signing of a comprehensive hosting and maintenance agreement with Scrubgrass Generating Company LLP and Bit5ive LLC; the successful addition of two new POD5IVE datacenters, which tripled the company’s active cryptocurrency mining fleet; the payoff of a major $363,000 convertible debt note; and the beneficial restructured Paradigm Home Health agreement terms, reflecting increasing revenue share from related operations by up to 40%. While Q1 2021 was a period of transition for ISWH’s investments in the telehealth/home healthcare sector, the company pointed out that total operations expanded during the quarter; the official recognition of those sales will be reflected in second-quarter numbers, as will the company’s growth in clientele. The company’s renewable energy cryptocurrency mining segment should also show its first tangible results in Q2 after significant investments over the past year. “Our current focus is on implementation of a renewable energy sourcing plan that will get our mining operations closer to the 0% carbon emission standard,” said Pierce. “We support the current technology industry roadmap of implementing and sourcing only renewable energy resources, and we believe this will enhance our net profitability over the long term. This was always our end game, which should be clear given our initial mining launch at the Pennsylvania renewable energy mining project. We are committed to a brighter, healthier and cleaner future.” For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• The 2021 Brazilian Mobius Launch begins with the FIFA World Cup Soccer Qualifiers
• With 76 million players, Brazil is the leading gaming nation in Latin America – showing 2020 industry earnings of $1.7 billion and estimates of 2.3 billion for 2021
• Brazil has become a major player in Esports. Mobius has the expertise and experience to take full advantage of this expanding market.

Mobius Interactive, an iGaming company, sees a bold future for gaming in Brazil. In 2020, Brazil’s gaming industry earned $1.7 billion with projections of $2.3 billion for 2021. Its ever-expanding base of 76 million gamers have made Brazil the leading gaming nation in Latin America. Now Mobius is leveraging the FIFA World Cup Soccer Qualifiers for its Brazilian launch. While the numbers in the stands will be impressive, the average television audience seeing the Mobius.bet brand will exceed 35 million viewers. CEO Lynn Pearce anticipates excellent results: “I don’t believe we could have wished for a better launchpad to introduce ourselves to the sports enthusiasts and betting community in this region” (https://ibn.fm/bRRfZ). In recent years, Brazil has shown significant growth in Esports. Many experts see Brazilian Esports as the most promising market in the world. There are now over 375 game developers in the country, a 180% increase from 2014.  Throughout 2020 and 2021, the appetite for Esports skyrocketed, as homebound sports fans searched for alternative outlets for their competitive spirits. According to PwC, the industry is expected to grow by 5.3% by 2022. It is not only sports fans who are flocking to this emerging industry. The general population is now taking up Esports gaming. CEO of INTZ, Lucas Almeida, states that engagement records on social media have gone from 8.3 million in February to 18 million in April. Brazil has now become a significant player in the Esports marketplace, ranking forth globally. Mobius has the experience and the team to reap maximum advantage from this growth. Mobius Interactive Ltd. launched in 2020. After years of successful operation in the industry, the Mobius team knew the time was right to strike. Within three months, they had delivered three distinct brands – Mobius.Bet, AragonCasino.com, and ClubDouble.com—setting a record in the iGaming industry. Collectively, the team at Mobius has over 40 years of industry experience, and have launched more than 30 successful products within the last three years. Since its launch, Mobius has seen continuous revenue growth, coupled with a conversion rate of new signups much higher than industry standards. The Mobius Team is laser-focused on the customer experience. Providing gamification throughout the entire player journey, the client remains on the platform longer. Real-time CRM systems ensure the entire player journey is both optimized and enjoyable, a win for investors and gamers alike. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Company names Dr. Carolyn Rachaner as director of product development and compliance
• Rachaner’s deep knowledge of nutrition, extensive education, understanding of product development make her pivotal player in company’s future
• One of the fastest-growing companies in social-marketing and direct-selling industries, the Happy Co. is building an entire business around happiness

Sharing Services Global (OTCQB: SHRG) — and its subsidiary the Happy Co. — have announced the appointment of direct-selling veteran Dr. Carolyn Rachaner to its new position of director of product development and compliance (https://ibn.fm/ynxZK). The Happy Co. is focused on health and wellness and offers an impressive line of natural nootropics products formulated to increase happiness, creativity, energy and focus. “Carolyn’s deep knowledge of nutrition and her extensive education and understanding of product development make her a pivotal player in the future of the Happy Co.,” said Bo Short, CEO of Elevacity Holdings LLC, the parent company of the Happy Co. “As we broaden our platform to include multiple categories of innovative products, it is vital that we bring this expertise in house. It is time to take that next big step forward, and Carolyn is the perfect choice to help us do just that.” Rachaner brings a wealth of experience and insight to her new position. She has accumulated an extensive resume that includes more than two decades serving primarily as a both a product educator and formulator in the health and wellness spaces. She also has racked up noteworthy global product development expertise. In addition, she operated a successful wellness center and built a highly successful nutritional consulting practice. She has earned a bachelor’s degree in nutrition and a doctorate in traditional naturopathy; she is also certified in applied clinical nutrition. One of the fastest-growing companies in the social-marketing and direct-selling industries, the Happy Co. is building an entire business around happiness. “Happiness is a universal desire,” says the company, which notes that “the world is our market [and] literally every person on earth wants what we offer” (https://ibn.fm/F6ynQ). And what the company offers is functional beverages, capsules, patches and creams, all carefully designed and formulated to elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin and make consumers look, feel and perform like a younger person. “Health and happiness go hand in hand, but few supplement companies are talking about how nutrition can impact our mental wellness,” said Rachaner. “To me, this is one of the most important aspects of health because when we feel good, we take better care of ourselves and it has a ripple effect throughout our lives and the lives of those around us. There has never been a better time for quality products that boost our mood and support all aspects of our health. The Happy Co. is well positioned to be the leader in this arena, and I am thrilled to be joining the team.” Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Stars are making bold statements about cannabis acceptance, efficacy as they enter cannabis business
• Lofty product claims may be seen as marketing ploys, but experts say there can be wellness benefits
• PACR’s strong focus, dedication differentiates it from other cannabis offerings, even those from big-name players in the cannabis space

A growing number of celebrities are throwing their weight behind cannabis, an undeniable indication of the increasing acceptance of the compound — both as a medical and recreational option. A recent “USA Today” article notes that as more states legalize marijuana, more eyes are turning toward the industry, a trend that leading cannabis companies such as Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) are in position to benefit from. “What do Martha Stewart, Jay-Z and Jaleel White (aka Steve Urkel) have in common?” the “USA Today” article asks. “They’re all in the cannabis business. They’re among many stars, including Snoop Dogg and Seth Rogen, who have joined the industry in recent years and are making bold statements with their products. Stewart’s self-named brand of CBD gummies claims to ‘make wellness an easier choice, every day,’ and Rogen’s Houseplant strain THC promises to give a ‘smooth, warm and calming experience.’ “These lofty product claims may be seen as marketing ploys in an increasingly competitive industry, but experts say there can be wellness benefits to some of these products,” states the article, which mentions that Kristen Bell, Willie Nelson, Gwyneth Paltrow and “Crazy Rich Asians” actor Jimmy O. Yang have also lent their names to cannabis products. Most celebrities are careful about what products they endorse, and the “USA Today” article notes that both cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), cannabinoids found in the marijuana plant, may be beneficial. The article quotes Washington, DC, MD Patricia Frye, who says both CBD and THC can help with sleep, anxiety, metabolism, stress and appetite. “These cannabinoids are so helpful, (because) people are starting to move away from a lot of pharmaceuticals,” Frye says. “Overall, it’s a lot safer than anything else you’d be using if you’re using it instead of opioids for pain or Ambien to help you sleep or instead of benzodiazepine for anxiety,” agreed Dr. Peter Grinspoon, a Harvard Medical School professor and a primary care doctor at Massachusetts General Hospital. Pac Roots Cannabis is a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach. The company’s commitment to quality and excellence is evident in its mantra of “quality over quantity” (https://ibn.fm/em2AR). Pac Roots is focused on elite genetic development and maximizes the quality of its offerings by keeping yields and profit margins high. The company also leverages key partnerships to ensure the superiority of its products. Those partnership include Phenome One, which has built one of the largest live genetic libraries in Canada, with more than 350 live cultivars; and Rock Creek Farms and Speakeasy Cannabis Club, both which provide existing infrastructure, equipment and access to land. “Our mission is to deliver the finest genetics to Canadians,” the company states. “Preserving the excellence of our elite strains while introducing the highest quality of new strains to the public is our passion. Genetic variation and stability are the foundation that drives the decision making for our business.” Such strong focus and dedication is sure to differentiate Pac Roots Cannabis — even setting it apart from the big-name players in the cannabis space. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Companies offering subscription services see significant spikes in numbers
• Through the Emaginos subscription service, all needed resources are provided to guide the schools and districts through implementation

Savvy companies are seeing the writing on the wall — and starting to offer subscription services for the bountiful benefits it provides. One recent article noted an impressive list of companies that had seen significant spikes in numbers, thanks to subscription services: Netflix reported 25% growth, Spotify saw 48% increase, and The New York Times experienced 43% growth while Stitch Fix reported 31% growth and Peloton noted an astounding 173% increase (https://ibn.fm/MxcIZ). Emaginos Inc. sees the potential for the subscription model in the education space and has created an education platform designed to revolutionize education in a way never before seen. “The subscription model business has been around for a long time, ever since publishers pioneered it in the 17th century,” the article noted. “Today, many brands offer products that are available via subscription – magazines, fitness clubs, software, and streaming services. But it wasn’t until the recent boom in subscription box companies that more and more brands started opening their eyes to the possibility of offering a subscription service, box-based or not. Before, you either were or you weren’t a subscription company. Now, many companies are realizing that definition was unnecessarily limited.” The subscription mode presents appealing potential for companies and investors alike. The Emaginos plan offers its game-changing Discovery Learning System(“DLS”) to schools and districts on a subscription basis. The system is built on a systemic transformation from the current teacher-centered model to a K-12 public education system that fosters a student’s desire to learn. Through this subscription service, all needed resources are provided to guide and support the schools and districts through their implementation of the Emaginos model, which transforms schools from the traditional “teaching and testing” approach to the more effective “learning and doing” approach that has been proven to result in significantly improved test scores and better overall student outcomes (https://ibn.fm/Ww5cW). An investment in education is an investment in the future on many levels. Financially, a recent study reported that the U.S. education market was estimated at more than $1.4 billion in 2018 and is forecast to reach $1.9 billion by 2025, reflecting a compound annual growth rate (“CAGR”) of 4.7% from 2019 to 2025 (https://ibn.fm/JKzgP). And beyond the black-and-white numbers, the importance of the country’s youth obtaining a quality education cannot be overestimated. “Education is a powerful force for promoting opportunity and growth,” noted a Brookings Institution report on K-12 education (https://ibn.fm/3nHZ8). “It is not surprising that an individual’s educational attainment is highly correlated with her income: college graduates generally earn more than less-educated Americans. What might be less obvious is that education is also a significant determinant of many other very important outcomes, including whether individuals marry, whether their children grow up in households with two parents, and even how long they will live. What’s more, on all of these dimensions, the gap between highly educated and less-educated Americans is getting bigger—in some cases, much bigger.” Emaginos is dedicated to closing that gap. The time for investing in better education has never looked more promising as Emaginos brings its first-to-market, actionable plan to the table. And the fact that the company is building this promise for the future around a subscription-based business model that utilizes existing funding, facilities and staff to improve educational approaches and outcomes, makes choosing Emaginos a no-brainer. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos